---
title: Spexin and Phoenixin-20 in Girls With Central Precocious Puberty
nct_id: NCT07359092
overall_status: COMPLETED
sponsor: Kayseri City Hospital
study_type: OBSERVATIONAL
primary_condition: Central Precocious Puberty (CPP)
countries: Turkey (Türkiye)
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT07359092.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07359092"
ct_last_update_post_date: 2026-01-22
last_seen_at: "2026-05-12T07:20:15.713Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Spexin and Phoenixin-20 in Girls With Central Precocious Puberty

**Official Title:** Comparison of Spexin and Phoenixin-20 Levels in Girls With Central Precocious Puberty, Premature Thelarche, and Healthy Controls

**NCT ID:** [NCT07359092](https://clinicaltrials.gov/study/NCT07359092)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 143
- **Lead Sponsor:** Kayseri City Hospital
- **Conditions:** Central Precocious Puberty (CPP), Puberty Disorders, Puberty, Hypothalamic-Pituitary-Ovarian Axis Dysfunction (Disorder)
- **Start Date:** 2024-12-01
- **Completion Date:** 2026-01-01
- **CT.gov Last Update:** 2026-01-22

## Brief Summary

Central precocious puberty (CPP) is characterized by the early activation of the hypothalamic-pituitary-gonadal axis in girls and may be difficult to distinguish from benign variants such as premature thelarche. Spexin and phoenixin-20 are novel neuropeptides that have been suggested to play roles in reproductive axis regulation.

The aim of this study was to compare serum spexin and phoenixin-20 levels among girls with central precocious puberty, girls with premature thelarche, and healthy age-matched controls. The study evaluated whether these biomarkers could help differentiate CPP from other conditions presenting with early breast development.

Clinical, anthropometric, and biochemical parameters were analyzed in all participants. Blood samples were collected and serum spexin and phoenixin-20 levels were measured using commercially available assay kits.

## Detailed Description

This was a prospective, observational study conducted in a pediatric endocrinology outpatient clinic. The study population consisted of girls younger than 8 years of age who presented between December 2024 and December 2025. Participants were categorized into three groups: girls diagnosed with central precocious puberty (CPP), girls with premature thelarche (PT), and healthy age-matched control subjects. The CPP group: 33 patients, PT group: 57 patients, and healthy controls: 53 patients.

The diagnosis of central precocious puberty was based on clinical findings, auxological data, bone age assessment, and hormonal evaluation according to standard pediatric endocrinology criteria. Premature thelarche was defined as isolated breast development without other signs of pubertal progression or activation of the hypothalamic-pituitary-gonadal axis.

Clinical and anthropometric data, including age, height, weight, body mass index, bone age, were recorded. Blood samples were obtained under standardized conditions, and also LH-RH stimulation test was applied in CPP and PT groups. Basal and stimulated FSH and LH hormone levels were examined. In addition, serum spexin and phoenixin-20 concentrations were measured using enzyme-linked immunosorbent assay kits in accordance with the manufacturers' instructions.

The primary objective of the study was to investigate whether serum spexin and phoenixin-20 levels differ between girls with CPP and those with PT or healthy controls, and whether these biomarkers could aid in distinguishing CPP from other causes of early pubertal signs.

## Eligibility

- **Minimum age:** 4 Years
- **Maximum age:** 8 Years
- **Sex:** FEMALE
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Female sex
* Age younger than 8 years,
* Presentation for evaluation of early pubertal signs (breast development)
* Classification into one of the following groups: central precocious puberty, premature thelarche, or healthy control

Exclusion Criteria:

* Presence of peripheral precocious puberty,
* Known chronic systemic disease,
* Use of medications affecting the hypothalamic-pituitary-gonadal axis,
* Known genetic syndromes of congenital endocrine disorders
```

## Arms

- **Central Precocious Puberty (CPP)** — Girls younger than 8 years diagnosed with CPP based on clinical findings (breast development stage) and LH-RH stimulation test peak LH level \>5 mIU/mL
- **Premature Thelarche (PT)** — Girls younger than 8 years presenting with isolated breast development and LH-RH stimulation test peak LH level \<5 mIU/mL
- **Healthy controls** — Age-matched healthy girls without signs of breast development

## Primary Outcomes

- **Serum Spexin and Phoenixin-20 levels** _(time frame: At initial clinical evaluation)_ — Comparison of serum Spexin and Phoenixin-20 concentrations among girls with central precocious puberty, premature thelarche, and healthy controls.

## Locations (1)

- Kayseri City Hospital, Kayseri, Turkey (Türkiye)

## Recent Field Changes (last 30 days)

- `design.enrollmentCount` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.kayseri city hospital|kayseri||turkey (türkiye)` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT07359092.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT07359092*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*